Convalescent Plasma News and Research

RSS
Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Chronic COVID-19 and divergent variants of SARS-CoV-2

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Failures and findings from randomized clinical trials in COVID-19 convalescent plasma

Failures and findings from randomized clinical trials in COVID-19 convalescent plasma

Characterizing the flexibility of SARS-CoV-2 variant of concern spike proteins

Characterizing the flexibility of SARS-CoV-2 variant of concern spike proteins

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

Study identifies broadly neutralizing antibody panel against SARS-like viruses

Study identifies broadly neutralizing antibody panel against SARS-like viruses

Convalescent plasma does not reduce risk of intubation or death for COVID-19 hospitalized patients

Convalescent plasma does not reduce risk of intubation or death for COVID-19 hospitalized patients

Highly neutralizing human convalescent plasma reduces lung inflammation in SARS-CoV-2-infected macaques

Highly neutralizing human convalescent plasma reduces lung inflammation in SARS-CoV-2-infected macaques

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Characterization of SARS-CoV-2 viral trajectory

Characterization of SARS-CoV-2 viral trajectory

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

The emergence and spread of the SARS-CoV-2 Lambda (B.1.621) variant

The emergence and spread of the SARS-CoV-2 Lambda (B.1.621) variant